XBI
State Street SPDR S&P Biotech ETF
SPDR S&P Biotech ETF seeks to replicate the performance of the S&P Biotechnology Select Industry Index, an equal-weighed index. The Index tracks all the US common stocks listed on the NYSE, Ame
US
EQUITY
Rules-Based
MANAGEMENT STYLE
$ 7.9 B
ASSETS UNDER MGMT
35 bp
EXPENSES
Fund Basics
| Inception date | Jan 31, 2006 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Quarterly |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| MODERNA, INC. | 2.2 % |
| ROIVANT SCIENCES LTD. | 1.7 % |
| VAXCYTE, INC. | 1.7 % |
| ARCELLX, INC. | 1.6 % |
| REVOLUTION MEDICINES, INC. | 1.6 % |
| PRAXIS PRECISION MEDICINES I | 1.6 % |
| AMGEN INC | 1.5 % |
| GILEAD SCIENCES INC | 1.5 % |
| AMICUS THERAPEUTICS INC | 1.5 % |
| MIRUM PHARMACEUTICALS, INC. | 1.4 % |
Constituent Breakdown
| Number of holdings | 137 |
| Herfindahl-Hirschman Index | 100 |
| Wgt avg mkt cap (mns) | $19,132 |
| Large cap (>$10bn) | 28.6% |
| Mid cap ($2-10bn) | 40.3% |
| Small cap (<$2bn) | 25.5% |
| Developed mkts. | 94.3% |
| Emerging mkts. | 0.0% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 89.0 % |
 |
BRITAIN | 1.7 % |
 |
IRELAND | 1.4 % |
 |
SWITZERLAND | 1.3 % |
 |
NETHERLANDS | 0.5 % |
Historical Performance
Standardized Performance (as of 02/28/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 4.5% | 43.6% | 13.8% | 15.4% | -3.0% | 10.3% | 10.4% | 10.8% |
| Dividend Yield | 0.0% | 0.5% | 0.3% | 0.2% | 0.1% | 0.2% | 0.3% | 0.3% |
| Total Returns | 4.5% | 44.1% | 14.1% | 15.6% | -2.8% | 10.4% | 10.7% | 11.1% | Ann. Volatility | 27.0% | 27.9% | 25.8% | 27.0% | 32.5% | 32.3% | 30.6% | 30.6% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.87 | 36% |
| MSCI EAFE | 0.95 | 31% |
| MSCI Emg Mkts | 0.77 | 25% |
Liquidity Measures
| Avg. volume (000) | 8,877 |
| ADV traded (mns) | $1,101 |
| Turnover | 14.0% |
| Avg. Bid/Ask (% of price) | 0.01% |
Technical Indicators
| 30d moving avg. (EMA) | $125.68 |
| Relative strength (RSI) | 55 |
| MACD/Signal | 0.75/0.52 |
| Bollinger Bands (Upper/Lower) | $129.69/$121.78 |
| Short interest (% of AUM) | 112.5% |
Distributions
Assets Under Management (mns)
Money Flows (mns)
Short Interest (as % of shares outstanding)
Long Money Flows (mns)
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. XBI |
Expenses vs. XBI |
ALTAR Score™ vs. XBI |
|---|---|---|---|---|
| BBP | Virtus LifeSci Biotech Products ETF | 45.1% | +44 bp | -4.3% |
| IBB | iShares Biotechnology ETF | 40.0% | +10 bp | -1.2% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 36.7% | -16 bp | -0.3% |
| WDNA | WisdomTree BioRevolution Fund | 34.0% | +10 bp | -3.7% |
| BBC | Virtus LifeSci Biotech Clinical Trials ETF | 32.0% | +44 bp | -0.6% |
| SBIO | ALPS Medical Breakthroughs ETF | 26.5% | +15 bp | -0.6% |
| FBT | First Trust NYSE Arca Biotechnology Index Fund | 24.9% | +21 bp | +1.5% |
| CANC | Tema Oncology ETF | 24.0% | +40 bp | -2.7% |
| PBE | Invesco Biotechnology & Genome ETF | 23.4% | +23 bp | +2.5% |
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 23.3% | +25 bp | +6.8% |
Risk and Returns: XBI vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 3/9/2026
Peer Group Comparison Sample data. Subscribe for access.
Price-to-Earnings
Price-to-Sales
Price-to-Book Value
Price-to-Cash Flow
Price-to-Growth
Dividend Yield
Historical Valuation Trends Sample data. Subscribe for access.
SHOWING:
Price-to-Earnings
Price-to-Earnings
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
0.6%
ALTAR SCORE™
1st
PERCENTILE
AVOID
ETFRC RATING
There are 1,191 funds in the US Equity category with an average
ALTAR Score™ of 5.6% and a standard deviation
of 2.0%. XBI's ALTAR Score™ is approximately -2.4 standard
deviations above the category average. This places XBI in the 1st percentile
among funds in the category.
Sell-Side Consensus
$167.62
PRICE TARGET
+35.2%
UPSIDE